AngioDynamics, Inc.
NASDAQ•ANGO
CEO: Mr. James C. Clemmer
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2004-06-01
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
Contact Information
Market Cap
$432.61M
P/E (TTM)
-13.9
58.7
Dividend Yield
--
52W High
$13.99
52W Low
$8.36
52W Range
Rank47Top 61.9%
3.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2026 Data
Revenue
$78.42M+0.00%
4-Quarter Trend
EPS
-$0.19+0.00%
4-Quarter Trend
FCF
-$4.13M+0.00%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Net Sales Growth Strong Six months net sales grew 10.6% to $155.1 M; Med Tech sales increased 19.1% over prior period.
Gross Margin Expansion Noted Total gross margin percentage improved 120 basis points to 55.8% for the six months ended November 30, 2025.
Net Loss Significantly Reduced Six months net loss decreased $6.3 M to $17.3 M, resulting in diluted loss per share of $0.42.
Operating Cash Flow Improved Cash used in operating activities improved $4.5 M to $(11.3) M for six months, reflecting better working capital.
Risk Factors
Port Product Liability Claims Defending approximately 268 Port Product Liability Claims; future litigation outcomes could materially impact financial estimates.
Sustained Profitability Lacking Full valuation allowance maintained on deferred tax assets; sustained profitability needed to potentially release allowance.
R&D Spending Increased R&D expense increased $1.5 M for six months to $14.2 M due to timing of clinical trial spending and projects.
Restructuring Charges Recorded Total restructuring charges reached $28.0 M related to manufacturing footprint optimization announced on January 5, 2024.
Outlook
Debt Position Remains Strong Zero outstanding debt as of November 30, 2025; $25.0 M secured revolving credit facility remains fully available.
CEO Transition Underway CEO transition underway; search committee established for successor, currently contemplated retirement date is November 30, 2026.
Liquidity Sufficient Short Term Current liquidity sufficient for next 12 months; external financing may be required for future acquisitions of businesses.
Restructuring Completion Expected Manufacturing footprint restructuring plan modification expected completion by end of fiscal year 2026, maintaining NY presence.
Peer Comparison
Revenue (TTM)
$854.40M
$381.14M
$313.73M
Gross Margin (Latest Quarter)
100.0%
97.7%
83.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| RAPT | $959.26M | -14.8 | -61.8% | 1.6% |
| CGEM | $868.55M | -3.9 | -46.2% | 0.6% |
| OMER | $852.43M | -224.5 | 1.7% | 73.4% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.7%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Deep Research
Next earnings:Jul 21, 2026
EPS:-$0.07
|Revenue:$80.24M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data